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constructed. Compared to the lowest quartile, adjusted dif-
ferences in the annual rates of decline (with 95% CI values
in parentheses) for the second, third and fourth quartiles 
were: TICS, –0.06 (–0.16, 0.03), –0.14 (–0.24, –0.04), and –0.09 
(–0.19, 0.01) points (p trend = 0.04); verbal memory, –0.01
(–0.04, 0.02), –0.05 (–0.08, –0.02), and –0.02 (–0.05, 0.01)
units (p trend = 0.02). These associations remained after mul-
tivariable adjustment.  Conclusions: Our study provides evi-
dence for a potential role of higher fasting insulin levels in 
cognitive decline, possibly independent of diabetes. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Type 2 diabetes mellitus has been associated with an 
increased risk of cognitive decline and dementia, includ-
ing Alzheimer disease, in numerous epidemiologic stud-
ies  [1–4] . Several mechanisms underlying this association 
have been proposed, including cerebrovascular disease 
that commonly accompanies type 2 diabetes mellitus, 
and toxic effects of chronic hyperglycemia and hyperin-
sulinemia  [4] . In particular, increasing evidence suggests 
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 Abstract 
 Background: Type 2 diabetes has been associated with an 
increased risk of dementia. To assess possible independent 
effects of insulin, we investigated the relation of insulin lev-
els to cognitive decline in nondiabetic women.  Methods: 
Fasting plasma insulin levels were measured in mid-life in 
1,416 nondiabetic Nurses’ Health Study participants, who 
also completed cognitive testing that began 10 years later 
(current age: 70–75 years). Over 4 years, 3 assessments of 
general cognition, verbal memory, category fluency and at-
tention were administered. Primary outcomes were the Tele-
phone Interview for Cognitive Status (TICS) performance, 
the global score (average of all tests) and verbal memory (av-
erage of verbal recall tests). Linear mixed-effects models 
were used to calculate the association between insulin and 
cognitive decline.  Results: Higher insulin levels were associ-
ated with a faster decline on the TICS and verbal memory. 
For analysis, batch-specific quartiles of insulin levels were 
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that higher insulin levels may increase the risk of cogni-
tive decline, even in the absence of clinical diabetes. 
While higher insulin may adversely affect brain health 
through vascular damage and inflammatory mecha-
nisms, it may have a more direct influence on specific 
Alzheimer pathologies, e.g. by interfering with amyloid-
  (A  ) metabolism in the brain, resulting in increased 
deposition of A  in plaques  [5] .
 To date, few studies have examined the effect of fasting 
insulin, independent of diabetes, on cognitive decline 
and dementia  [6, 7] . We previously reported an associa-
tion between higher levels of C-peptide (a measure of in-
sulin production) and impaired performance on a single 
cognitive assessment in a subset of Nurses’ Health Study 
(NHS) participants without diabetes  [8] . In the present 
study, we sought to assess the robustness of this relation 
by examining the longitudinal association between fast-
ing plasma insulin levels and decline on 3 repeated cogni-
tive assessments conducted over 4 years in a much larger 
sample of nondiabetic women in the NHS.
 Methods 
 Study Population 
 The Nurses’ Health Study (NHS) began in 1976 and included 
121,700 registered female nurses, aged 30–55 years. Participants 
completed biennial mailed questionnaires updating information 
on lifestyle and health outcomes, including whether they were 
diagnosed with diabetes. In addition, 21,095 women provided 
fasting blood samples drawn between 1989 and 1990. Health and 
lifestyle characteristics were very similar between the whole co-
hort and those who provided blood samples. The total follow-up 
for these women exceeds 98.0%.
 Beginning in 1995, NHS participants aged 70 years and over, 
free of diagnosed stroke, were invited to participate in a tele-
phone-based study of cognitive function, and 19,395 (93.3%) com-
pleted an initial cognitive assessment. Since then, 2 follow-up as-
sessments have been performed approximately 2 years apart. Fol-
low-up remains over 90%.
 Of the women for whom fasting blood samples from the 1989–
1990 collection were available, 3,915 were in the cognitive study 
and had completed 2 follow-up assessments. Participation rates in 
the cognitive study were similar in those who had and had not 
provided blood, suggesting little possibility for bias in examining 
associations in those providing blood samples  [8] . We measured 
fasting insulin in a random sample of 1,068 women without diag-
nosed diabetes at blood draw. To increase power, we added an-
other 348 nondiabetic women (all of whom were participants in 
the cognitive study, with 2 completed follow-up assessments) with 
available measures of fasting insulin obtained using blood sam-
ples from the 1989–1990 collection. Fasting insulin had been as-
sayed when these women were selected as controls in prior nested 
case-control studies of diabetes (n = 75) and hypertension (n = 
76), or as cases and controls (n = 197) in a previous nested case-
control study of breast cancer. We included both cases and con-
trols from the breast cancer study, rather than just controls, as 
breast cancer case status is not related to cognition in our data  [8] . 
This yielded a final sample for analysis of 1,416 women.
 This study was approved by the Institutional Review Board of 
Brigham and Women’s Hospital, Boston, Mass., USA.
 Fasting Insulin Measurements 
 Using fasting blood samples that had been stored at –130 ° C, 
we measured plasma insulin levels with a radioimmunoassay spe-
cific for insulin (Linco, St. Louis, Mo., USA), based on an antise-
rum with less than 1% cross-reactivity for proinsulin and des-31, 
32-proinsulin. In blinded quality control tests, intra-assay coef-
ficients of variation for all batches were  ! 10%.
 Cognitive Function 
 Cognitive testing included: the Telephone Interview for Cog-
nitive Status (TICS)  [9] , a telephone-based test of general cogni-
tion similar to the Mini-Mental State Examination  [10] ; immedi-
ate and delayed recalls of the East Boston Memory Test  [11] to 
assess verbal memory; a test of category fluency, in which women 
named as many different animals as possible during 1 minute; a 
delayed recall of the TICS 10-word list; and digit span backward, 
in which women repeated an increasingly long series of digits 
backwards, to evaluate attention and working memory.
 General cognition and verbal memory were our 2 primary 
outcomes; in particular, verbal memory is a strong predictor of 
early Alzheimer disease  [12, 13] . To assess general cognition, we 
used the TICS, as well as a global cognitive score, calculated by 
averaging the z scores of all 6 cognitive tests. To calculate a verbal 
memory score, we combined the results of the immediate and de-
layed recalls of both the East Boston Memory Test and the TICS 
10-word list, by averaging z scores of the 4 individual tests  [8] . 
The global score and verbal memory score were only calculated 
for participants who had completed all component tests.
 Data Analysis 
 To examine the association of plasma insulin levels with cog-
nitive decline, batch-specific quartiles of insulin levels were con-
structed; the lowest quartile was used as the reference category. 
We used linear mixed-effects models  [14] to examine the associa-
tion between fasting insulin and changes in cognitive scores 
across the 3 assessments. Basic models were adjusted for age at 
baseline cognitive interview and highest attained education. Mul-
tivariable models further adjusted for other potential confound-
ers, determined at the time of blood draw: BMI, current smoking 
(yes/no), history of hypertension (yes/no), history of elevated cho-
lesterol (yes/no), history of heart disease (yes/no), alcohol use (g/
day), physical activity (metabolic equivalents per week), and post-
menopausal hormone use (yes/no).
 In the mixed-effects models, we included time since baseline 
interview (in years), age, education, fasting insulin quartile, as 
well as interaction terms for time and age, and time and fasting 
insulin quartile as fixed effects; in the multivariable mixed mod-
els, we also included the other potential confounders as fixed ef-
fects. In addition to the fixed effects, we included 2 person-spe-
cific random effects: baseline cognitive level (random intercept) 
and rate of change (random slope). The interaction terms for time 
and fasting insulin quartile from these mixed models represented 
the annual rate of cognitive decline associated with fasting insu-
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lin across the 3 assessments (mean interval from first to third as-
sessment = 4.3 years).
 Secondary Analyses 
 Since depression may influence cognitive performance, we re-
peated the analyses adjusting for regular antidepressant use at the 
time of baseline cognitive assessment. Regular use of antidepres-
sants was utilized as the depression variable, since data on depres-
sion scores were not available at the time of baseline testing.
 To examine whether diabetes or stroke occurring during cog-
nitive follow-up may be responsible for any observed associations, 
we conducted secondary analyses in which we excluded partici-
pants who were diagnosed with diabetes mellitus at any time after 
blood draw, or with stroke after the baseline cognitive assess-
ment.
 Finally, we repeated our analyses in only those 1,068 women 
who were in the random sample.
 Results 
 Table 1 shows the characteristics of the study sample 
at the time of blood draw, across quartiles of fasting in-
sulin levels. As expected, higher levels of fasting insulin 
tended to be associated with higher BMI, higher preva-
lence of hypertension and elevated cholesterol, and lower 
alcohol intake, physical activity and postmenopausal 
hormone use.
 Unadjusted scores on baseline cognitive tests, across 
fasting insulin quartiles, are shown in  table 2 . In general, 
those with higher insulin levels tended to have lower 
mean scores on category fluency and digit span back-
ward, and also appeared to have worse cognitive perfor-
mance on the global and verbal memory scores.
 When we examined cognitive decline across 3 cogni-
tive assessments over an average of 4 years, we found sig-
Table 1. Characteristics at time of the 1989-1990 blood draw, across quartiles of insulin levels
1st quartile 2nd quartile 3rd quartile 4th quartile
(n = 355) (n = 353) (n = 354) (n = 354)
Median insulin, IU/ml 2.1 2.7 3.9 6.7
Mean age at blood draw, years 64.0 64.1 64.4 64.3
Master’s or doctorate degree, % 8.3 6.8 9.0 4.8
Mean body mass index 23.4 24.2 25.3 27.7
Current smoking, % 8.3 11.6 9.0 8.6
History of hypertension, % 21.1 24.1 33.2 46.6
History of elevated cholesterol, % 30.4 34.2 34.9 39.0
History of heart disease, % 1.5 1.0 1.5 1.5
Mean alcohol use, g/day 6.1 6.4 5.0 3.9
Mean physical activity, metabolic
equivalent-hours/week 18.4 18.6 17.6 14.4
Current postmenopausal hormone use, % 36.2 33.7 29.6 25.2
Table 2. Baseline cognitive test scores across quartiles of fasting insulin
Cognitive test 1st quartile 2nd quartile 3rd quartile 4th quartile
TICS 34.282.4 34.282.5 34.182.4 34.282.4
EBMT, immediate recall 9.681.6 9.581.7 9.781.7 9.681.7
EBMT, delayed recall 9.381.9 9.281.8 9.381.8 9.381.8
Category fluency 18.184.8 17.784.5 17.484.6 17.384.4
10-word list, delayed recall 2.581.9 2.581.9 2.382.0 2.581.9
Digit span backward 7.282.3 6.982.4 6.882.4 6.682.2
Global cognition z score 0.0380.59 –0.0180.62 –0.0180.57 –0.0380.57
Verbal cognition z score –0.0180.68 –0.0280.71 0.0080.67 –0.0080.67
Values are presented as means 8 SD. EBMT = East Boston Memory Test.
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nificantly worse decline on both the TICS and the verbal 
score with increased fasting insulin levels ( table 3 ). Spe-
cifically, compared to the first quartile, the annual rates 
of decline (with 95% CI values in parentheses) for the sec-
ond, third and fourth quartiles were: TICS, –0.06 (–0.16, 
0.03), –0.14 (–0.24, –0.04) and –0.09 (–0.19, 0.01) points 
(p trend = 0.04);  verbal memory score, –0.01 (–0.04, 0.02), 
–0.05 (–0.08, –0.02) and –0.02 (–0.05, 0.01) standard 
units (p trend = 0.02). Multivariable-adjusted estimates 
remained similar; compared to the first quartile, the an-
nual rates of decline for the second, third and fourth 
quartiles were: TICS, –0.05 (–0.15, 0.05), –0.12 (–0.22, 
–0.03) and –0.10 (–0.19, 0.00) points (p trend = 0.06); ver-
bal memory score, –0.02 (–0.05, 0.01), –0.05 (–0.08, –0.02) 
and –0.03 (–0.06, 0.00) standard units (p trend = 0.02).
 In secondary analyses, adding regular antidepressant 
use to the multivariable model produced nearly identical 
results. Similarly, further exclusion of women who re-
ported either a diagnosis of diabetes mellitus after blood 
draw or stroke after the baseline cognitive assessment did 
not affect our estimates, e.g. compared to the first quar-
tile, the age-and-education-adjusted annual rates of de-
cline for the second, third and fourth quartiles were: 
TICS, –0.06 (–0.15, 0.04), –0.14 (–0.23, –0.04) and –0.09 
(–0.19, 0.01) points (p trend = 0.05); verbal memory score, 
–0.01 (–0.04, 0.02), –0.05 (–0.08, –0.02) and –0.02 (–0.05, 
0.01) standard units (p trend = 0.02). Finally, after re-
stricting our analyses to only women in the random sam-
ple (n = 1,068), estimates were again unchanged.
 Discussion 
 In women without type 2 diabetes mellitus at blood 
draw, we found that higher levels of fasting insulin were 
associated with faster rates of cognitive decline. Associa-
tions were independent of numerous potential confound-
ing factors and persisted after the exclusion of women 
who were diagnosed with diabetes mellitus or stroke after 
the baseline cognitive interview. Although the largest 
point estimates for rates of cognitive decline were found 
in the third and not in the fourth quartile, the p trends 
were significant across quartiles for the TICS and verbal 
memory, supporting a dose-effect relationship.
 Although there are very few studies of insulin levels 
and cognition in nondiabetics, our findings are consis-
tent with previous studies linking higher fasting insulin 
levels to cognitive impairment  [15] , dementia  [6] and cog-
nitive decline  [6] in healthy subjects. For example, among 
386 nondiabetic men, those in the highest quartile of fast-
ing insulin level had 25% more errors on the Mini-Mental 
State Examination compared with those in the lowest 
quartile  [15] . Luchsinger et al.  [6]  reported an association 
between higher insulin and an increased risk of dementia 
in persons without diabetes (hazard ratio = 2.3, 95% CI = 
1.5–3.6); an association between insulin and decline in 
memory-related cognitive scores was also found. Though 
not directly examining fasting insulin levels, other stud-
ies support the hypothesis of a role of insulin in the de-
velopment of cognitive impairment. Yaffe et al.  [16] 
 showed an elevated risk of developing cognitive impair-
ment in women with impaired fasting glucose but with-
out diabetes (fasting glucose level  1 6.1 mmol/l but  ! 7.0 
mmol/l), compared to women with a normal fasting glu-
cose. Recently, higher glycosylated hemoglobin levels 
were associated with an increased risk of mild cognitive 
impairment and dementia in 1,983 women; these asso-
ciations remained after the exclusion of women with di-
agnosed diabetes  [17] .
 In this NHS cohort, we previously reported an asso-
ciation between higher levels of C-peptide (a measure of 
insulin production) and cognitive impairment  among 
718 women  [8] ; we found similar results for C-peptide 
among 367 men in the Physicians’ Health Study  [18] . 
However, in these 2 studies, complete information from 
cognitive testing was only available from a single exami-
Table 3. Mean differences in cognitive decline across quartiles of fasting insulin
Cognitive test 1st quartile 2nd quartile 3rd quartile 4th quartile p trend
TICS 0.00 –0.06 (–0.16 to 0.03) –0.14 (–0.24 to –0.04) –0.09 (–0.19 to 0.01) 0.04
Global score 0.00 –0.01 (–0.03 to 0.02) –0.03 (–0.05 to 0.00) –0.01 (–0.04 to 0.01) 0.16
Verbal score 0.00 –0.01 (–0.04 to 0.02) –0.05 (–0.08 to –0.02) –0.02 (–0.05 to 0.01) 0.02
Values represent mean differences in the annual rate of decline on cognitive test scores compared to the first quartile over an aver-
age of 4 years, and have been adjusted for age and highest attained education. The 95% CI values are given in parentheses.
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nation. Thus, the current study adds substantively to the 
literature by showing a significant relation between high-
er fasting insulin levels and increased rates of decline 
over time on repeated assessments of cognition – in par-
ticular, a decline in verbal memory, a key predictor of 
dementia  [12, 13] .
 In addition, growing biologic evidence supports a role 
of insulin in cognitive decline and dementia  [19] . It has 
been shown that peripheral insulin is actively transport-
ed across the blood-brain barrier  [20] , and insulin recep-
tors have been found throughout the brain, in particular 
in the hippocampus and cortex  [21] . Moreover, it has been 
suggested that high insulin levels in the brain may di-
rectly interfere with A  metabolism by inhibiting degra-
dation of A  by insulin-degrading enzyme, resulting in 
increased deposition of A  in plaques  [5] . Thus, insulin 
may directly affect specific Alzheimer pathologies. Ad-
ditionally, it is likely that part of the relation of insulin to 
cognition and dementia is mediated by vascular disease, 
although, in our study and in others, adjustment for 
known major vascular factors did not affect the associa-
tion between insulin and cognitive decline. However, it is 
difficult to accurately measure the presence of subclinical 
vascular disease. Indeed, it seems plausible that a combi-
nation of both direct (e.g. increased brain A  ) and indi-
rect effects (e.g. inflammation or vascular endothelial 
damage) of elevated insulin may underlie the observed 
association with cognitive decline.
 The strengths of this study include the high rate of fol-
low-up and the breadth of information on potential con-
founding factors, updated every 2 years. In addition, fast-
ing insulin levels were measured in blood collected in 
mid-life; since cognitive impairment appears to take 
many years to develop, risk factors at these younger ages 
may be the most important assessment.
 Potential limitations of our study should be consid-
ered. First, information on cognitive decline was gath-
ered through telephone-based testing rather than through 
in-person testing. However, the high validity of our tele-
phone method has been established  [8] ; furthermore, the 
telephone testing yields high participation and follow-up 
rates, enhancing the validity of results. Second, we only 
had a single measurement of insulin, which may have in-
creased random measurement error; however, this would 
have led to an underestimation of the association be-
tween insulin and cognitive decline. Third, this is a select 
population of largely healthy Caucasian nurses, and the 
absolute levels of fasting insulin were somewhat lower 
than those recently reported in nondiabetic, community-
dwelling women of comparable age  [22, 23] . However, a 
slightly narrower distribution of fasting insulin levels 
would lead, if anything, to underestimating the relation 
between insulin and cognitive decline in the general pop-
ulation; indeed, the significant association we found be-
tween insulin and cognitive decline in these healthy 
women with relatively low levels of insulin emphasizes 
the potential importance of even modestly elevated insu-
lin. Fourth, since we relied on self-reports of diabetes sta-
tus to exclude diabetic women, our study sample may 
have included women with undiagnosed diabetes melli-
tus; hence, our findings may partly be explained by the 
association between diabetes and cognitive decline. How-
ever, as noted earlier, insulin levels in this sample were 
not very high, indicating a low prevalence of insulin re-
sistance, and our results remained similar when we ex-
cluded women who were diagnosed with diabetes melli-
tus during follow-up, likely eliminating any women with 
undiagnosed diabetes mellitus at the time of blood draw. 
Moreover, as health professionals, virtually all our par-
ticipants have access to health care, making undiagnosed 
diabetes mellitus less likely; indeed, in a random sample 
of 200 NHS participants who never reported diabetes, we 
found only 1 had a plasma fasting glucose or fructos-
amine level in the diabetic range  [8] . Finally, although we 
were able to adjust for many potential confounders, re-
sidual confounding should be considered, as in any ob-
servational study. The relative homogeneity of our co-
hort, however, reduces the potential effect of many un-
measured confounders, such as health knowledge and 
access.
 In conclusion, data from our study suggest a role of 
insulin, independent of diabetes mellitus, in the develop-
ment of cognitive decline. This association clearly needs 
further research since modulation of insulin levels may 
represent an effective target for prevention of cognitive 
decline and Alzheimer disease.
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